1011722-07-8Relevant articles and documents
Visible Light-Induced Borylation of C-O, C-N, and C-X Bonds
Arman, Hadi D.,Dang, Hang. T.,Haug, Graham C.,He, Ru,Jin, Shengfei,Larionov, Oleg V.,Nguyen, Viet D.,Nguyen, Vu T.,Schanze, Kirk S.
, (2020)
Boronic acids are centrally important functional motifs and synthetic precursors. Visible light-induced borylation may provide access to structurally diverse boronates, but a broadly efficient photocatalytic borylation method that can effect borylation of a wide range of substrates, including strong C-O bonds, remains elusive. Herein, we report a general, metal-free visible light-induced photocatalytic borylation platform that enables borylation of electron-rich derivatives of phenols and anilines, chloroarenes, as well as other haloarenes. The reaction exhibits excellent functional group tolerance, as demonstrated by the borylation of a range of structurally complex substrates. Remarkably, the reaction is catalyzed by phenothiazine, a simple organic photocatalyst with MW 200 that mediates the previously unachievable visible light-induced single electron reduction of phenol derivatives with reduction potentials as negative as approximately - 3 V versus SCE by a proton-coupled electron transfer mechanism. Mechanistic studies point to the crucial role of the photocatalyst-base interaction.
Pyridineacetamide derivative serving as CDK inhibitor, and preparation method and application thereof
-
Paragraph 0557-0562, (2021/07/28)
The invention belongs to the technical field of pyridineacetamide derivatives, and particularly relates to a pyridineacetamide derivative serving as a CDK inhibitor and a preparation method and application of the pyridine acetamide derivative. The pyridineacetamide derivative shows excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing drugs used for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors such as breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.
Method for continuously producing pyridylboronic acid
-
Paragraph 0051-0098, (2020/06/17)
The invention provides a method for continuously producing pyridylboronic acid. The method comprises the following steps: reacting a first reaction raw material with a second reaction raw material ina micro-channel reactor to generate a first reaction product; reacting the first reaction product with hydrochloric acid in a micro-channel reactor to obtain a crude reaction solution; and carrying out post-treatment on the obtained crude reaction solution to obtain the pyridine boric acid product. The first reaction raw material is an organic solution of alkyl lithium or phenyl lithium; and the second reaction raw material is a mixture composed of 2-cyano-5-bromopyridine, alkyl borate and an organic solvent. According to the method disclosed by the invention, the characteristics of strong mass transfer and heat transfer effects of the micro-channel reactor are utilized, and the first reaction raw material, the second reaction raw material and hydrochloric acid are promoted to be fully mixed in an extremely small structural size, and a large amount of heat released by the reaction is taken away in time, so that the reaction time is shortened by 20 times or more, the energy consumptionis remarkably reduced, the productivity is remarkably improved, and the method has the great social value.